High Transcript Level of FLT3 Associated with High Risk of Relapse in Pediatric Acute Myeloid Leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Hyoung Jin | - |
dc.contributor.author | Lee, Ji Won | - |
dc.contributor.author | Kho, Sang Hyeok | - |
dc.contributor.author | Kim, Min Jeong | - |
dc.contributor.author | Seo,Young Jin | - |
dc.contributor.author | Kim, Hyery | - |
dc.contributor.author | Shin, Hee Young | - |
dc.contributor.author | Ahn, Hyo Seop | - |
dc.date.accessioned | 2022-05-18T00:40:28Z | - |
dc.date.available | 2022-05-18T00:40:28Z | - |
dc.date.issued | 2010-06 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/cau/handle/2019.sw.cau/57765 | - |
dc.description.abstract | Identification of prognostic factors and risk-based post-remission therapy was proposed to improve the outcomes of acute myeloid leukemia (AML) and a mutation of FLT3 has been reported to be a risk factor, especially for pediatric patients. Recently, FLT3 expression level was implicated to have prognostic significance in adults, but little is known for childhood AML. To define the prognostic significance, transcript level of FLT3 was analyzed in 52 pediatric AML patients. The median copy number of FLT3 was 4.6 x 10(3) (40-5.9 x 10(7) copies)/1.0 x 10(6) GAPDH copy, and the relapse free survival of patients with high transcript level of FLT3 (>10(6) copy number) (0%) was significantly lower than that of the others (53.2%). High transcript level of FLT3 was associated with a markedly high risk of relapse. The development of new therapeutic scheme such as a frontline allogeneic stem cell transplantation or administration of FLT3 inhibitor is needed to improve outcomes. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | KOREAN ACAD MEDICAL SCIENCES | - |
dc.title | High Transcript Level of FLT3 Associated with High Risk of Relapse in Pediatric Acute Myeloid Leukemia | - |
dc.type | Article | - |
dc.identifier.doi | 10.3346/jkms.2010.25.6.841 | - |
dc.identifier.bibliographicCitation | JOURNAL OF KOREAN MEDICAL SCIENCE, v.25, no.6, pp 841 - 845 | - |
dc.identifier.kciid | ART001446250 | - |
dc.description.isOpenAccess | Y | - |
dc.identifier.wosid | 000278477200006 | - |
dc.identifier.scopusid | 2-s2.0-77956413528 | - |
dc.citation.endPage | 845 | - |
dc.citation.number | 6 | - |
dc.citation.startPage | 841 | - |
dc.citation.title | JOURNAL OF KOREAN MEDICAL SCIENCE | - |
dc.citation.volume | 25 | - |
dc.type.docType | Article | - |
dc.publisher.location | 대한민국 | - |
dc.subject.keywordAuthor | FLT3 | - |
dc.subject.keywordAuthor | Transcript Level | - |
dc.subject.keywordAuthor | Leukemia, Myeloid, Acute | - |
dc.subject.keywordAuthor | Pediatric Age | - |
dc.subject.keywordPlus | INTERNAL TANDEM DUPLICATION | - |
dc.subject.keywordPlus | STEM-CELL TRANSPLANTATION | - |
dc.subject.keywordPlus | BONE-MARROW-TRANSPLANTATION | - |
dc.subject.keywordPlus | PROGNOSTIC-SIGNIFICANCE | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | EXPRESSION | - |
dc.subject.keywordPlus | MUTATIONS | - |
dc.subject.keywordPlus | RECEPTOR | - |
dc.subject.keywordPlus | CHILDREN | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
84, Heukseok-ro, Dongjak-gu, Seoul, Republic of Korea (06974)02-820-6194
COPYRIGHT 2019 Chung-Ang University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.